. GKT831 achieves marked anti-fibrotic effects in clinically relevant model of advanced cholestatic disease

. Interim results of the Phase 2 Clinical Trial with GKT831 in Primary Biliary Cholangitis expected in early November 2018

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today the presentation of preclinical data showing that GKT831, the Company’s clinical stage NOX1 and NOX4 inhibitor, efficiently targeted cancer associated fibroblasts (CAFs) in prostate cancer and abrogated the pro-tumorigenic influence of the tumor micro-environment. The results were presented by Dr. Natalie Sampson, Division of Experimental Urology, Dept. of Urology, Medical University of Innsbruck, Austria, at ESUR18 – the 25th Meeting of the European Association of Urology, taking place October 4-6, 2018, in Athens, Greece (ESUR18, October 5, Poster #P-23).
More information on : https://www.newcontact.eu/secure/media/com_newcap/files/files/Genkyotex_20181015_PR_AASLD%202018_ENG_clean.pdf